Centro de Investigacion del Maule | Talca, Chile

Research site

(Unclaimed)

Location

30 oriente 1562, talca, Región Metropolitana de Santiago, Chile

Site insights

Top conditions

Top treatments

Astegolimab

Vicadrostat

BI 1015550

Rocatinlimab

GLPG1690

BI 1291583

BI 690517

Nalbuphine

PLN-74809

Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 16 total trials

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast (FIBRONEER™-ON)

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling

Progressive Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Drug: Nerandomilast

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum d...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Astegolimab

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Enrolling

Heart Failure

Drug: Placebo

Drug: empagliflozin

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and...

Enrolling

Bronchiectasis

Drug: Placebo matching BI 1291583

Drug: BI 1291583